

¹ **Detection, not mortality, constrains the evolution of**
² **virulence**

³ David A. Kennedy

⁴ Department of Biology, Center for Infectious Disease Dynamics, The Pennsylvania State

⁵ University, University Park, PA, USA

⁶ E-mail: dak30@psu.edu

⁷ **Abstract**

⁸ Why would a pathogen evolve to kill its hosts when killing a host ends a pathogen's own
⁹ opportunity for transmission? A vast body of scientific literature has attempted to answer
¹⁰ this question using "trade-off theory," which posits that host mortality persists due to its
¹¹ cost being balanced by benefits of other traits that correlate with host mortality. The
¹² most commonly invoked trade-off is the mortality-transmission trade-off, where increasingly
¹³ harmful pathogens are assumed to transmit at higher rates from hosts while the hosts are
¹⁴ alive, but the pathogens truncate their infectious period by killing their hosts. Here I show
¹⁵ that costs of mortality are too small to plausibly constrain the evolution of disease severity
¹⁶ except in systems where survival is rare. I alternatively propose that disease severity can
¹⁷ be much more readily constrained by a cost of behavioral change due to the detection of
¹⁸ infection, whereby increasingly harmful pathogens have increasing likelihood of detection
¹⁹ and behavioral change following detection, thereby limiting opportunities for transmission.
²⁰ Using a mathematical model, I show the conditions under which detection can limit disease

²¹ severity. Ultimately, this argument may explain why empirical support for trade-off theory
²² has been limited and mixed.

²³ **Introduction**

²⁴ The seminal works of Anderson and May (Anderson and May 1982; May and Anderson 1983)
²⁵ changed the way that biologists thought about the evolution of pathogen virulence, defined
²⁶ as the severity of disease signs or symptoms caused by infection with a particular pathogen.
²⁷ Before Anderson and May, the conventional wisdom was that pathogens would evolve to
²⁸ be avirulent over time (Alizon and Michalakis 2015), since a highly virulent pathogen risks
²⁹ killing its host and by killing its host a pathogen truncates its own infectious period and
³⁰ reduces its own fitness. Anderson and May articulated that natural selection favors pathogen
³¹ variants that maximize their own fitness. If virulence were correlated with other epidemi-
³² logical parameters such as infectiousness or time to recovery, intermediate levels of virulence
³³ could maximize fitness, and thus be evolutionarily adaptive. The idea they proposed, “trade-
³⁴ off theory”, is that the cost of virulence, which they assumed was a truncated duration of
³⁵ infectiousness caused by host mortality, trades off against other benefits such as an increased
³⁶ rate of transmission or a decreased rate of recovery. This work has been hugely influential,
³⁷ and the trade-off theory that they proposed has since been termed the “new conventional
³⁸ wisdom” (Alizon et al. 2009). Ultimately, trade-off theory was meant to explain why evolu-
³⁹ tion has generated pathogens that have intermediate levels of virulence. That is, 1) why do
⁴⁰ pathogens harm their hosts at all, and 2) why do they not harm their hosts more?

41 There are only a limited number of explanations for why evolution has allowed pathogens
42 to maintain virulence. Either there is no genetic variation for reduced virulence, selection is
43 too weak to eliminate virulence entirely, or virulence is associated with some fitness benefit
44 to the pathogen (Alizon and Michalakis 2015). Although it is possible to point to specific
45 examples where each of these explanations might apply, the widespread detection of variation
46 in virulence (e.g., Froissart et al. 2010) and the observation that virulence often increases
47 during serial passage experiments (Ebert 1998) challenge the generality of these first two
48 explanations. In contrast, a recent meta-analysis of experimental studies on virulence evo-
49 lution found that replication rates within hosts positively correlates with both transmission
50 potential and virulence (Acevedo et al. 2019), lending support to the third explanation. It
51 has thus been generally accepted that, for most pathogens, some degree of virulence provides
52 or is correlated with a fitness benefit in some environment where selection is acting.

53 This leaves the question of why pathogens are not more harmful to their hosts. Classical
54 trade-off theory proposes that pathogens are not more harmful to their hosts because the
55 fitness benefits associated with increased virulence saturate relative to the fitness costs of
56 increased virulence (Alizon et al. 2009). Translated to a mathematical framework, the typ-
57 ical assumption is that increases in transmission rate saturate relative to increases in host
58 mortality (Fig. 1). Such a relationship may emerge due to within host processes (Alizon
59 and van Baalen 2005), and has been seen in some biological systems (e.g. De Roode et al.
60 2008; Read et al. 2015), but this saturation has not been generally detected (Acevedo et al.
61 2019). In fact, experimental data in support of trade-off theory has been disappointingly

62 limited (Bull 1994; Lipsitch and Moxon 1997; Alizon et al. 2009; Alizon and Michalakis 2015;
63 Cressler et al. 2016), leading to questions about the usefulness of trade-off theory entirely
64 (Lipsitch and Moxon 1997; Ebert and Bull 2003; Bull and Lauring 2014).

65 Rather than disregard trade-off theory, some have argued that the lack of experimental
66 support for trade-off theory has resulted from difficulties in designing appropriate experi-
67 ments (Alizon and Michalakis 2015) or from collecting inappropriate proxies for virulence
68 and transmission (Cressler et al. 2016). I argue that the reason few experiments have found
69 evidence supporting trade-off theory is that they assume the cost of virulence is borne out
70 through a reduction in the duration of infections due to host mortality, despite the fact that
71 this is rarely the case.

72 Behavior and behavioral changes are being increasingly recognized as important drivers
73 of infectious disease dynamics in humans (Funk et al. 2010) and other animals (Stockmaier
74 et al. 2021). Changes in behavior alone are capable of tipping the balance from localized
75 pathogen extinction to successful disease emergence (Alexander and McNutt 2010; Shaw and
76 Kennedy 2021). Pathogen-induced changes in behavior could therefore impose substantial
77 selection pressure. For example, if contact rates between hosts declined with increasing dis-
78 ease severity, there could be strong selection pressure on the pathogen to reduce its severity.
79 Such a relationship between disease severity and contact rates has been observed (McKay
80 et al. 2020), yet with few exceptions (e.g. Ewald 1983, 1994), the role of behavior on virulence
81 evolution has been largely ignored. The fact that disease ecology is rarely driven by host
82 mortality but can often be driven by host behavior might lead one to wonder whether changes

83 in behavior following infection are generally a stronger evolutionary force than changes in
84 mortality.

85 Here I argue that the cost of virulence typically plays out through morbidity-induced
86 reductions in contact rates – which I refer to as a “detection cost of virulence” – and that
87 this cost of virulence drastically outweighs the cost of infection induced mortality for the vast
88 majority of systems. Note that this argument builds on several previously published con-
89 cepts. Ewald (1983, 1994) long ago proposed a trade-off between virulence and transmission
90 mode that implicitly included a virulence-detection trade-off. This idea was later formalized
91 (Day 2001, 2002a), and the concept has been discussed by many others (for example, Alizon
92 and Michalakis 2015; McKay et al. 2020). Likewise, Ebert and Bull (2003) and Bull and
93 Lauring (2014) previously discussed that virulence, in the context of mortality, is likely to
94 impose only an indirect and weak evolutionary cost.

95 Here I show that, under the assumptions of a mortality-rate-transmission-rate trade-off,
96 the cost of virulence can be written in terms of the infection fatality rate (defined as the
97 fraction of all infections, symptomatic and asymptomatic, that result in disease-induced
98 host death). Using this new form, I show that mortality is too weak a cost to constrain the
99 virulence of pathogens in most systems, but that detection costs can.

100 **Model and Results**

101 **The cost of mortality**

102 The original formulation of the virulence-transmission trade-off arises from analysis of a
103 classic SIR model based on the models of Kermack and McKendrick (1991) and Anderson
104 and May (1979).

$$\frac{dS}{dt} = r(1 - N) + \phi R - \beta SI - \mu S, \quad (1)$$

$$\frac{dI}{dt} = \beta SI - \alpha I - \gamma I - \mu I, \quad (2)$$

$$\frac{dR}{dt} = \gamma I - \phi R - \mu R. \quad (3)$$

105 Above, S , I , and R are the respective densities of susceptible, infectious, and recovered
106 hosts. N is the total population density derived by summing S , I , and R . r is the maximum
107 per capita birth rate, ϕ is that rate at which immunity wanes, β is the transmission rate,
108 γ is the recovery rate, μ is the baseline host mortality rate, and α is the pathogen-induced
109 host mortality rate.

110 Under the assumptions of this model and any model that excludes non-linear environmen-
111 tal feedbacks such as spatial structure (Boots et al. 2004; Berngruber et al. 2015), coinfection
112 (May and Nowak 1995), superinfection (Nowak and May 1994), host heterogeneity (Regoes
113 et al. 2000), and non-linear transmission (Lion and Metz 2018), a pathogen strain that maxi-

114 mizes the basic reproductive number R_0 will competitively exclude all other pathogen strains
115 once the system reaches an equilibrium. It thus follows that natural selection will lead to
116 the evolution of a pathogen strain that maximizes R_0 (Anderson and May 1982).

117 In the above model, the basic reproductive number is

$$R_0 = \frac{\beta N}{\alpha + \gamma + \mu} \quad (4)$$

118 This formulation of R_0 illustrates the paradox of virulence pointed out by May and Anderson
119 (1983). That is, all else equal, a strain with lower virulence (i.e. smaller α) would have a
120 higher R_0 , and thus, pathogens should evolve to be avirulent. However, if transmission rate
121 β or recovery rate γ were functions of virulence, it need not be the case that low virulence is
122 always favored. Famously, R_0 can be maximized at intermediate virulence if the transmission
123 rate β is a saturating function of host induced mortality α (Fig. 1). This so called virulence-
124 transmission trade-off is by far the most widely invoked explanation for the maintenance of
125 virulence in nature.

126 According to the principle of R_0 maximization, a new pathogen variant would be able
127 to invade and displace an existing pathogen strain provided the new value of R_0 is greater
128 than the old value of R_0 . Under the assumption that recovery rate γ is the same for two
129 pathogen variants, this can be reduced to (Supplemental Information):

$$\frac{\Delta\alpha}{\alpha_n + \gamma + \mu} < \frac{\Delta\beta}{\beta_n} \quad (5)$$

130 Above, I use the symbol Δ as shorthand for the difference between the old and new values
131 for a parameter, such that ΔX corresponds to $X_n - X_o$, where subscript “ n ” denotes the
132 new variant and subscript “ o ” denotes the old variant. Inequality 5 leads to the well known
133 result that if the transmission rate β is a saturating function of disease induced mortality
134 rate α , then an optimal level of virulence can be derived as shown in Fig 1.

135 In a classical SIR model such as that described by Eq. 1-3 the infection fatality rate F ,
136 defined as the fraction of all infections that result in disease-induced death, can be written
137 as $F = \frac{\alpha}{\alpha + \gamma + \mu}$. Note that the infection fatality rate is similar to the case fatality rate except
138 that the latter often excludes asymptomatic infections. Under the assumption that recovery
139 rates do not differ between variants (Day 2002b), Inequality 5 can be rewritten in terms of
140 F , leading to the conclusion that a new mutation will spread if (Supplemental Information):

$$\frac{\Delta F}{1 - F_o} < \frac{\Delta \beta}{\beta_n} \quad (6)$$

141 The above inequality states that a new variant will be able to invade and displace the
142 current pathogen if the percentage decrease in infection survival rate $1 - F$, is less than the
143 percentage increase in the transmission rate β . Note that the left side of this inequality can
144 be viewed as the costs of virulence and the right side can be viewed as the benefits.

145 The advantage of Inequality 6 over the standard formulation (Inequality 5) is that it
146 shows that the cost of mortality depends on percent changes in survival rather than percent
147 changes in mortality. For a pathogen with low survival (i.e. $F_o \approx 1$), small changes in
148 mortality can thus generate large constraints, but for pathogens with high survival (i.e.

₁₄₉ $F_o \approx 0$), small changes in mortality generate small constraints since the denominator on
₁₅₀ the left hand side is approximately 1. The consequence of this asymmetry means that
₁₅₁ for pathogens with initially low infection fatality rates, almost all variants with increased
₁₅₂ transmission and virulence should be able to invade and spread. The fact that low virulence
₁₅₃ pathogens retain low virulence, however, suggests that there is something wrong with the
₁₅₄ theory.

₁₅₅ To illustrate this point, consider a theoretical pathogen with a low infection fatality rate
₁₅₆ $F_o \approx 0$, something akin to a rhinovirus that causes the common cold. If this pathogen has
₁₅₇ an R_0 of 5 and an infection duration of 5 days, then that implies each infection produces
₁₅₈ 1 new infection per day. Inequality 6 tells us that a mutation that increased its per day
₁₅₉ infectiousness from 1.00 to 1.01 would be evolutionarily favored provided it did not increase
₁₆₀ the infection fatality rate above approximately 1%. Notably, a 1% change in transmission is
₁₆₁ small relative to differences in transmission rates typically detected between field isolates (e.g.
₁₆₂ Mackinnon and Read 1999), but this change in mortality rate is larger than the difference
₁₆₃ between a common-cold-causing rhinovirus and SARS-CoV-2 (O'Driscoll et al. 2021). Theory
₁₆₄ thus predicts that if the main cost of virulence were host mortality, the common cold could
₁₆₅ become as severe as COVID-19 in exchange for a 1% increase in the transmission rate of the
₁₆₆ virus. Yet no such variant has ever spread, and there has never even been a documented
₁₆₇ cluster of rhinovirus infections with COVID-like mortality rates. Similarly, an increase in
₁₆₈ transmission rate from 1.00 to 1.10 could justify an infection fatality rate as high as 9%, which
₁₆₉ is comparable to the infection fatality rate of the 2003 SARS virus (Parry 2003). Nearly

₁₇₀ identical numbers can be derived for pathogens and parasites that are typically thought of
₁₇₁ as moderately virulent, such as influenza A viruses, measles virus, *Plasmodium falciparum*,
₁₇₂ and SARS-CoV-2 (Fig. 2).

₁₇₃ Under the above theory, mortality only provides a strong cost of virulence to pathogens
₁₇₄ with extremely high infection fatality rate F (Fig. 3) such as for lethal, chronic infections
₁₇₅ like human immunodeficiency virus (HIV, Fraser et al. 2014). One is therefore left to wonder
₁₇₆ what typically constrains disease severity if not infection-induced mortality.

₁₇₇ The cost of detection

₁₇₈ I propose that a more reasonable mechanism constraining virulence is a reduction in trans-
₁₇₉ mission attributable to behavioral changes that follow detection of infection. For instance,
₁₈₀ once someone realizes they have COVID-19 symptoms, they may self-isolate thereby reduc-
₁₈₁ ing transmission opportunities. Alternatively, an infected host may simply feel too sick to
₁₈₂ conduct their normal daily activities such as attend school or go to work, again reducing
₁₈₃ transmission opportunities. In either case, causing detectable infection would negatively
₁₈₄ impact pathogen fitness, and presumably, moreso for increasingly severe disease.

₁₈₅ To formalize this concept, consider an alternative SIR-type model, with modification from
₁₈₆ Eqs 1-3. The differences are that 1) host mortality has been removed, and 2) the infectious
₁₈₇ class has been split up into three groups.

$$\frac{dS}{dt} = r(1 - N) + \phi R - \beta S(I_e + I_n + (1 - f)I_d), \quad (7)$$

$$\frac{dI_e}{dt} = \beta S(I_e + I_n + (1 - f)I_d) - \frac{\gamma}{1 - \epsilon} I_e, \quad (8)$$

$$\frac{dI_n}{dt} = (1 - D) \frac{\gamma}{1 - \epsilon} I_e - \frac{\gamma}{\epsilon} I_n, \quad (9)$$

$$\frac{dI_d}{dt} = D \frac{\gamma}{1 - \epsilon} I_e - \frac{\gamma}{\epsilon} I_d, \quad (10)$$

$$\frac{dR}{dt} = \frac{\gamma}{\epsilon} (I_n + I_d) - \phi R. \quad (11)$$

188 As before, N is the sum of host density in all classes, S is the density of susceptible hosts,
 189 and R is the density of recovered hosts. I_e tracks hosts in the early phase of infection in
 190 which detection of infection is not yet possible, and I_n and I_d track hosts in the later phase
 191 of infection for respectively not detected and detected infections. As before, the parameter
 192 ϕ is the rate at which immunity wanes, γ is the rate of recovery of infected individuals, and
 193 β is the transmission rate in the absence of detection. The parameter f is the reduction in
 194 transmission of detected infections relative to non-detected infections, ϵ is the fraction of an
 195 infection's duration that occurs after detection is possible, and D is the fraction of infections
 196 that are detected. Note that the new parameters f , ϵ , and D are bounded between 0 and 1,
 197 while the reused parameters ϕ , β and γ can still take any non-negative value.

198 As before, we can readily derive the basic reproductive number,

$$R_0 = \frac{\beta N(1 - \epsilon f D)}{\gamma}. \quad (12)$$

199 This formulation of R_0 demonstrates the cost of detection as described by the parameter
 200 combination $\epsilon f D$. Note that this parameter combination describes the fraction of new
 201 infections that are avoided because of pathogen detection. It can be conceptualized as
 202 the fractional reduction in transmission that occurs over the lifetime of an infection due
 203 to detection. This may be realized through, for example, a reduction in contact rate or a
 204 reduction in infectiousness given contact. More highly virulent pathogens presumably lead
 205 to detection in a larger fraction of hosts (i.e. increased D), and more stringent actions to
 206 reduce transmission once detected (i.e. increased f) (McKay et al. 2020). This effect is only
 207 borne out for ϵ , the fraction of each infection that occurs after detection is possible. The net
 208 effect of these morbidity effects is to decrease overall transmission opportunities and thus R_0 .
 209 If we assume that increased disease severity correlates with increased transmission potential
 210 in the absence of detection β , as appears to be the case (Acevedo et al. 2019), then it is
 211 possible for R_0 to be maximized at intermediate levels.

212 As before, a new pathogen variant would be able to displace an existing pathogen if the
 213 new value of R_0 is greater than the old value of R_0 . As with a mortality cost, I assume the
 214 recovery rate γ is unchanged by evolution of virulence (i.e. no trade-off between virulence
 215 and recovery). If ϵ , the fraction of an infection that occurs after detection is possible, is also
 216 unchanged by evolution, then a new variant will be capable of invading if (Supplemental
 217 Information):

$$\frac{\epsilon \Delta(fD)}{1 - \epsilon f_o D_o} < \frac{\Delta\beta}{\beta_n} \quad (13)$$

218 Above, $\epsilon\Delta(fD)$ is the change in transmission caused by the detection of infections and it
219 is defined as ϵ times $f_nD_n - f_oD_o$. The other parameters are as described above. Note that
220 if we relaxed the assumption that ϵ was unchanged by evolution, the numerator on the left
221 hand side would have instead been $\Delta(\epsilon fD)$. Regardless, this inequality states that a more
222 harmful variant would be favored by evolution if the percent decrease in ineffective control is
223 less than the percent increase in the transmission rate in the absence of detection. Notice the
224 parallels with the analogous result using the classic virulence-transmission trade-off, where
225 the key inequality was that the percent decrease in survival must be less than the percent
226 increase in transmission. Hosts that survive continue to transmit analogously to how hosts
227 with undetected infections or ineffective interventions continue to transmit.

228 Nevertheless, there is a key difference between Inequalities 6 and 13. I previously showed
229 using an example that host mortality is unlikely to constrain the evolution of pathogen
230 virulence for pathogens with initially low infection fatality rates F_o . Again consider the
231 same hypothetical pathogen with an infection duration of 5 days and an R_0 of 5, but this
232 time, focus on the cost of detection. Assume individuals can be infectious 1 day before
233 developing symptoms and 4 days after. Also, assume that an individual becomes less likely
234 to attend school, work, or other social events with increasingly severe symptoms, and that
235 the vast majority of transmission occurs during these activities. Using this information, we
236 can ask under what circumstances a new variant that causes the average person to stay
237 home one day would be able to displace a less severe variant that causes the average person
238 to not stay home at all (i.e. virtually no initial cost of virulence as in the mortality cost

example above). Using the above details, we can calculate the key parameters: $\epsilon = 4/5$, $f_n D_n = 1/4$, $f_o D_o = 0$. Plugging these values into Inequality 13 leads to the conclusion that this variant would only be able to invade if it were accompanied by a 20% or larger increase in transmission. This can be visualized in Fig. 3 if the x-axis label was changed from “infection fatality rate (F)” to “the reduction in transmission due to detection ($\epsilon f D$)”.

If we were to put this example with detection costs on the same scale as the previous example with mortality costs, transitioning from a 0% infection fatality rate to a 1% infection fatality rate is an equivalent cost to transitioning from a 0% chance of staying home for one day to a 5% chance. While the former would almost certainly be documented if it were to evolve in human populations, the latter almost certainly would not. Again, these changes would only be evolutionarily favored if they led to an increase in transmission of approximately 1% or more (Inequalities 6 and 13).

Presumably many infectious diseases, including non-human diseases, could be constrained by costs of detection. However, detection would not have much impact on limiting disease severity if large fractions of the infectious period occurred prior to the time when detection would be possible (i.e. ϵ is small), if reductions in transmission were small following the detection of infection (i.e. f_o is small) or if a very small fraction of infections were detected (i.e. D_o is small). Likewise, host-induced mortality can be a strong constraint on virulence evolution if the infection fatality rate F_o is large. To determine whether virulence is more strongly shaped by a mortality-transmission trade-off or a detection-transmission trade-off,

259 one can combine Inequalities 6 and 13 to ask:

$$\frac{\Delta F}{1 - F_o} \stackrel{?}{>} \frac{\epsilon \Delta(fD)}{1 - \epsilon f_o D_o}. \quad (14)$$

260 When the left-hand side of the above expression is larger than the right-hand side, mortality
261 will impose a stronger constraint on virulence evolution than detection, and vice versa. For
262 a pathogen with low virulence, the denominators on both sides are close to one meaning that
263 we can visualize this inequality using only the numerators (Fig. 4). This demonstrates that
264 for pathogens with relatively low virulence, detection will generally be a stronger constraint
265 on virulence evolution than mortality.

266 Discussion

267 The new conventional wisdom says that pathogens evolve to balance the cost and benefits
268 of virulence and its associated traits. Typically, the cost of virulence is assumed to be a
269 truncated infectious period due to disease-induced host mortality. Here I have argued that
270 this cost is too weak in most systems to constrain virulence. To do this, I have rewritten the
271 virulence-transmission trade-off equation in terms of infection fatality rate (i.e. the fraction
272 of infections that result in host death F) rather than in terms of the per day infection-
273 induced death rate (i.e. α). This formulation makes explicit that mortality-based evolution of
274 virulence theory predicts that a novel variant would be able to displace an existing pathogen
275 variant if the percent decrease in host survival is less than the percent increase in the rate

276 of transmission (Inequality 6). However, this is an extremely weak evolutionary force for
277 all but the most virulent pathogens (Figs. 2 and 3). I instead propose that the main cost
278 of virulence is due to behavioral changes that result from the detection of infection. Using
279 a modified SIR model that explicitly allows for costs of detection, I show that a detection
280 cost can be a much stronger constraint on virulence evolution than host-induced mortality
281 (Fig. 4).

282 It has previously been noted that costs of mortality are small (Ebert and Bull 2003; Bull
283 and Lauring 2014). I provide an analytical expression for precisely how small (Inequality
284 6). This expression states that when infection fatality rates are low, a percent change in
285 transmission rate can balance an equivalent absolute change in the infection fatality rate
286 (Figs. 2 and 3). Under the assumption that mortality limits disease severity, a 1% increase
287 in transmission can thus justify something as harmless as a virus that causes the common
288 cold evolving to become something as deadly as SARS-CoV-2, yet a common cold virus has
289 never evolved to be so deadly. Certainly something else must constrain virulence.

290 Host behavior, unlike host mortality, is widely recognized to influence infectious disease
291 dynamics (Funk et al. 2010; Stockmaier et al. 2021). It only stands to reason then, that
292 when infection-induced behavioral changes affect opportunities for onward transmission, and
293 disease severity alters the degree of behavioral change, there will be opportunities for natural
294 selection to shape disease severity. This idea was originally made by Ewald (1983, 1994)
295 to argue that vector transmitted diseases should evolve to be more virulent than directly
296 transmitted diseases since they do not rely on their hosts for dispersal. However, definitive

297 data supporting Ewald's argument regarding transmission mode are still lacking (Leggett
298 et al. 2017). While a disconnect between his assumptions and his conclusions may be due
299 to variation in system specific details (Day 2002a), support for mortality costs in the case of
300 myxomatosis (Fenner 1983; Dwyer et al. 1990) led to mortality being viewed as a reasonable
301 constraint on virulence evolution. I have shown that this is not the case when infection
302 fatality rates are low, and it may explain why surprisingly few data support the idea that
303 mortality acts as a constraint on pathogen evolution (Bull 1994; Lipsitch and Moxon 1997;
304 Ebert and Bull 2003; Alizon et al. 2009; Bull and Lauring 2014; Cressler et al. 2016; Acevedo
305 et al. 2019).

306 At some level, this conclusion may be obvious. Both mortality and detection could in
307 principle constrain virulence evolution, but death is usually a rare outcome of infection
308 whereas detection is usually a common outcome. It thus follows that detection costs may
309 often be larger than mortality costs.

310 Few data are yet available to quantify precisely how large detection costs are, but the data
311 that do exist suggest these costs are quite large in comparison to fully asymptomatic infec-
312 tions. A study of influenza-like-illness (ILI) during the 2009 influenza pandemic found that
313 people with ILI reduced their per day contacts by 75%, and the average duration of contact
314 also declined (Van Kerckhove et al. 2013). Despite this reduction, two thirds of transmission
315 was attributable to symptomatic infection, suggesting a steep trade-off between contact rate
316 and infectiousness given contact (Van Kerckhove et al. 2013). Another study using seasonal
317 influenza documented a negative correlation between morbidity scores and activity levels

318 among people with detected infections, and even proposed that this reduction in activity
319 may pose a constraint on virulence evolution in that system (McKay et al. 2020). Similarly,
320 a survey study on behavioral change following diagnosis with various sexually transmitted
321 diseases reported that 71% of men modified their behavior (e.g. increased condom use, re-
322 duced frequency of sex, etc.) following diagnosis. Isolation and quarantine following the
323 detection of SARS-CoV-2 infection in an individual or in a close contact of an individual
324 likewise is thought to have large impacts on disease transmission (Keeling et al. 2020). Nev-
325 ertheless, more data are still needed to establish whether the magnitude of these detection
326 costs are typical for human diseases.

327 Similar magnitude effects are seen in the animal world. When wild house mice were
328 experimentally injected with lipopolysaccharide (LPS) to induce disease symptoms, 40% of
329 the mice disconnected entirely from their social groups (Lopes et al. 2016). Although these
330 mice did not have an infectious disease, the change in behavior brought on by a general
331 immune response would have substantially reduced opportunities for pathogen transmission
332 if it were brought on by a pathogen (Lopes et al. 2016). Vampire bats injected with LPS also
333 showed large changes in behavior, with 85% less time spent grooming conspecifics and 19%
334 less time spent being groomed by conspecifics (Stockmaier et al. 2020). Analogous patterns
335 were found in guppies infected with an ectoparasite. Guppies typically form groups called
336 shoals, but when infected guppies were added to otherwise healthy populations, the healthy
337 fish actively avoided the infected guppies causing fission events at twice the rate of controls,
338 and associations when they did occur were half as long in duration (Croft et al. 2011).

339 In a eusocial ant species, when colony workers were experimentally infected with a fungal
340 pathogen, the social network of the colony changed in ways that reduced opportunities for
341 disease transmission, including a shift such that experimentally infected worker ants spent
342 20% more time outside of the nest than controls (Stroeymeyt et al. 2018).

343 Notably, detection costs may even be playing a role in limiting virulence for some of the
344 systems where virulence-transmission trade-offs have been best documented. For example, in
345 *Mycoplasma gallisepticum* where prior immune history enhances the spread of highly virulent
346 strains (Fleming-Davies et al. 2018), interaction rates between birds are approximately 15%
347 lower for infected birds than non-infected birds (Faustino et al. 2004). Likewise, for monarch
348 butterflies infected with the parasite *Ophryocystis elektroscirrrha*, reductions in mating suc-
349 cess that prevent transmission to offspring actually provide a stronger constraint on parasite
350 load than mortality, captured as pupal emergence (De Roode et al. 2008), although perhaps
351 not significantly so.

352 While the above data may be subject to some of the same publication biases that have
353 previously plagued trade-off theory (Acevedo et al. 2019), the effects in the above studies
354 tend to be highly significant and a mechanistic basis for the effects seem logical (Ewald 1983,
355 1994). Moreover, there is a long history of humans altering their behavior in response to the
356 detection of infectious disease (Curtis 2014).

357 Admittedly, the model described in Eqs. 7-11 is more complicated than absolutely nec-
358 essary. Very similar conclusions could have been derived from a standard SIR model where
359 the transmission rate β is separated into two components, the rate of contact and the proba-

360 bility of infection given contact. In that model, if the rate of contact declines with increasing
361 virulence, that cost could constrain virulence evolution (Day 2001, 2002a). However, it is
362 difficult to intuit the reasonableness of changing these parameters since they are composite
363 parameters like transmission rate itself. By introducing the biologically meaningful param-
364 eters ϵ , f , and D , I hope to have provided a clearer framework for thinking about the basis
365 of detection costs.

366 Along similar lines, I have followed the standard SIR model assumption that mortality
367 risk is constant for the duration of an infection. This is typically not true, with mortality
368 typically occurring towards the later phase of infection. If this were incorporated into my
369 analysis, the effect is that the cost of mortality would be even weaker than I have calculated,
370 further strengthening my claim that mortality costs are typically too weak to constrain
371 virulence evolution.

372 Note that despite the use of the term “detection cost”, my argument is agnostic as to
373 the exact mechanism causing the change in interactions. Multiple mechanisms can result
374 in reduced transmission, and have been documented in human and non-human hosts. De-
375 tected infections can result in reduced transmission if infected hosts are too ill to go about
376 their normal routine and thus contact fewer susceptible hosts (e.g. Stockmaier et al. 2020),
377 if they take action to avoid spreading an infection through intentional behavioral modifica-
378 tion (e.g. Süß et al. 2011; Stockmaier et al. 2021), if they seek treatment to end infection
379 earlier (e.g. Alizon 2020), or even if they are avoided by others who notice that they are ill
380 (e.g. Curtis 2014)).

381 Perhaps the greatest challenge moving forward is to test this theory experimentally. The
382 difficulty of doing so stems from being able to create conditions that are close enough to field
383 conditions such that they allow for changes in behavior that limit transmission following the
384 detection of infection. Such laboratory experiments may prove too difficult to design, and
385 may ultimately mean that tests of this theory must be performed in the field.

386 It is worth noting that virulence has been defined differently by different researcher
387 (Read 1994; Thomas and Elkinton 2004; Alizon and Michalakis 2015; Cressler et al. 2016).
388 For example, virulence can be defined as the pathogen induced reduction in host fitness
389 (Read et al. 2015), as the per day pathogen-induced host mortality rate (Anderson and
390 May 1982), as the fraction of hosts that die from infection (Day 2002b), or in numerous
391 other ways (Thomas and Elkinton 2004; Cressler et al. 2016), and these differences can lead
392 to fundamentally different conclusions (Day 2002b). Here I have defined virulence as the
393 severity of disease signs or symptoms caused by infection with a pathogen. The argument
394 that I have put forward applies to this definition of virulence specifically. While it may apply
395 to other definitions of virulence as well, this application relies on correlations in “virulence
396 scores” between the definitions.

397 Despite my above argument, there are some situations in which a mortality cost can
398 provide a stronger constraint on the evolution of virulence than a detection cost (Inequality
399 14, Fig. 4). For example, mortality costs appear to have been major drivers of pathogen
400 evolution for myxomatosis (Fenner 1983), Marek’s disease virus (Read et al. 2015), and
401 some bacteriophages (Messenger et al. 1999). Notably, accounting for pathogen-induced host

402 mortality is important for accurately modeling disease dynamics in these systems (Dwyer
403 et al. 1990; Berngruber et al. 2013; Atkins et al. 2013).

404 Here I have assumed that the benefits of virulence come from a correlation with trans-
405 mission rate (Fig. 1). As shown by Inequality 14, the precise benefit of virulence does not
406 impact whether virulence is more strongly constrained by mortality or detection. Numerous
407 alternative theories have been proposed to explain why pathogens maintain virulence even
408 in cases where virulence itself is not obviously beneficial (Frank 1996; Alizon and Michalakis
409 2015; Cressler et al. 2016). Some of these theories include that multilevel selection leads to
410 the evolution of virulence levels that are non-optimal at the between-host scale (e.g. Levin
411 and Bull 1994; Mideo et al. 2008), that spatial structure imposes dispersal or persistence
412 costs of high virulence (e.g. Boots et al. 2004), that environmental feedbacks limit the rela-
413 tionship between the basic reproductive number R_0 and optimal virulence (Lion and Metz
414 2018), that virulence is not adaptive in the context where it is being studied but adaptive
415 in another context (Ebert 1999), that bottlenecks prevent the evolution of optimal virulence
416 (Bergstrom et al. 1999), or simply that there is no heritable variation for virulence on which
417 selection can act. Notably, these theories have largely been developed to explain why trade-
418 off theory seems not to apply generally, and while the theoretical impacts of these factors
419 have been demonstrated, the extent to which they play out in the real world is still unknown.

420 Assuming detection is a main factor in limiting the evolution of virulence, it begs the
421 question of how this knowledge might be used. Ebert and Bull (2003) previously argued that
422 virulence management is not practical when it relies on indirect selection using trade-off the-

423 ory. They instead proposed that efforts would be better aimed towards selecting against
424 virulence directly. I propose that if virulence is truly constrained by a cost of detection,
425 then efforts to increase detection would leverage trade-off theory while also directly selecting
426 against virulence, provided the increased detection effort maintains the correlation between
427 detection and virulence. Likewise, as we saw during the early days of the COVID-19 pan-
428 demic, surveillance programs are often designed to catch clusters of symptomatic infection
429 (Kerr et al. 2021). This may unintentionally provide additional evolutionary benefits in that
430 more virulent pathogens will be more likely to be caught and stopped.

431 **Acknowledgments**

432 I thank T. Day, G. Dwyer, and A. Read for comments on previous versions of the text. This
433 work was supported by National Science Foundation grant DEB-1754692. The funders had
434 no role in study design, data collection and analysis, decision to publish, or preparation of
435 the manuscript.

⁴³⁶ **Supplemental Information**

⁴³⁷ **Classic virulence-transmission trade-off**

⁴³⁸ Under what conditions will a new mutation n be able to invade and displace an original
⁴³⁹ pathogen variant o . Assuming Eqs. 1-3, a new mutation can invade when:

$$R_{0,n} > R_{0,o}. \quad (15)$$

⁴⁴⁰ Substituting equation 4 into inequality 5 yields

$$\frac{\beta_n N}{\alpha_n + \gamma_n + \mu} > \frac{\beta_o N}{\alpha_o + \gamma_o + \mu}. \quad (16)$$

⁴⁴¹ Multiplying both sides by $\alpha_o + \gamma_o + \mu$ and dividing both sides by $\beta_n N$ yields

$$\frac{\alpha_o + \gamma_o + \mu}{\alpha_n + \gamma_n + \mu} > \frac{\beta_o}{\beta_n}. \quad (17)$$

⁴⁴² Multiplying both sides by negative 1 and then adding 1 to each side yields

$$\frac{\alpha_n - \alpha_o + \gamma_n - \gamma_o}{\alpha_n + \gamma_n + \mu} < \frac{\beta_n - \beta_o}{\beta_n}. \quad (18)$$

443 Under the assumptions of a virulence-transmission trade-off constrained by disease-induced

444 mortality, $\gamma_o = \gamma_n$ and so the above can be rewritten

$$\frac{\Delta\alpha}{\alpha_n + \gamma + \mu} < \frac{\Delta\beta}{\beta_n}. \quad (19)$$

445 where $\Delta\alpha \equiv \alpha_n - \alpha_o$ and $\Delta\beta \equiv \beta_n - \beta_o$.

446 **Rewriting the virulence-transmission trade-off in terms of F**

447 In the model described by Eqs. 1-3, there are two ways an infected host can leave the

448 infected class I : 1) through death caused by infection and 2) through recovery. Since both

449 the infection-induced mortality rate α and the recovery rate γ are assumed to be constants

450 over time in the standard SIR model, the fraction of hosts that leave the infected class

451 through infection-induced death is simply described by the equation (Day (2002b) previously

452 presented the generalization where rates are variable over time):

$$F = \frac{\alpha}{\alpha + \gamma + \mu}. \quad (20)$$

453 I use the above equation to solve for α_o in terms of F_o and γ_o , which yields

$$\alpha_o = (\gamma_o + \mu) \frac{F_o}{1 - F_o} \quad (21)$$

454 Returning to eq. 19, substituting in eq. 21 for α_o and the equivalent for α_n , and then
 455 simplifying gives

$$\frac{\Delta F}{1 - F_o} < \frac{\Delta \beta}{\beta_n} \quad (22)$$

456 where $\Delta F \equiv F_n - F_o$ and $\Delta \beta \equiv \beta_n - \beta_o$. Inequality 22 thus shows that a new mutation will
 457 be favored if the percent change in the infection survival rate is less than the percent change
 458 in the transmission rate.

459 **Detection costs**

460 Starting from Eq. 12, a new mutation can invade when:

$$\frac{\beta_n N (1 - \epsilon_n f_n D_n)}{\gamma_n} > \frac{\beta_o N (1 - \epsilon_o f_o D_o)}{\gamma_o}. \quad (23)$$

461 Multiplying both sides by γ_o and dividing both sides by $\beta_o N (1 - \epsilon_o f_o D_o)$ yields:

$$\frac{\gamma_o (1 - \epsilon_n f_n D_n)}{\gamma_n (1 - \epsilon_o f_o D_o)} > \frac{\beta_o}{\beta_n}. \quad (24)$$

462 Again multiplying both sides by negative 1 and adding 1 to each side yields:

$$\frac{\gamma_n (1 - \epsilon_o f_o D_o) - \gamma_o (1 - \epsilon_n f_n D_n)}{\gamma_n (1 - \epsilon_o f_o D_o)} < \frac{\beta_n - \beta_o}{\beta_n}. \quad (25)$$

463 Assuming $\gamma_n = \gamma_o$, we arrive at our final solution:

$$\frac{\Delta(\epsilon f D)}{1 - \epsilon_o f_o D_o} < \frac{\Delta\beta}{\beta_n}. \quad (26)$$

464 References

465 ACEVEDO, M. A., DILLEMUTH, F. P., FLICK, A. J., FALDYN, M. J., AND ELDERD,
466 B. D. 2019. Virulence-driven trade-offs in disease transmission: A meta-analysis. *Evolution*
467 73:636–647.

468 ALEXANDER, K. A. AND MCNUTT, J. W. 2010. Human behavior influences infectious dis-
469 ease emergence at the human–animal interface. *Frontiers in Ecology and the Environment*
470 8:522–526.

471 ALIZON, S. 2020. Treating symptomatic infections and the co-evolution of virulence and
472 drug resistance. *bioRxiv* .

473 ALIZON, S., HURFORD, A., MIDEO, N., AND VAN BAALEN, M. 2009. Virulence evolution
474 and the trade-off hypothesis: history, current state of affairs and the future. *Journal of*
475 *Evolutionary Biology* 22:245–259.

476 ALIZON, S. AND MICHALAKIS, Y. 2015. Adaptive virulence evolution: the good old fitness-
477 based approach. *Trends in Ecology & Evolution* 30:248–254.

478 ALIZON, S. AND VAN BAALEN, M. 2005. Emergence of a convex trade-off between trans-
479 mission and virulence. *The American Naturalist* 165:E155–E167.

480 ANDERSON, R. M. AND MAY, R. M. 1979. Population biology of infectious diseases: Part
481 I. *Nature* 280:361–367.

482 ANDERSON, R. M. AND MAY, R. M. 1982. Coevolution of hosts and parasites. *Parasitology*
483 85:411–426.

484 ATKINS, K. E., READ, A. F., SAVILL, N. J., RENZ, K. G., ISLAM, A. F. M., WALKDEN-
485 BROWN, S. W., AND WOOLHOUSE, M. E. J. 2013. Vaccination and reduced cohort du-
486 ration can drive virulence evolution: Marek’s disease virus and industrialized agriculture.
487 *Evolution* 67:851–860.

488 BERGSTROM, C. T., MCELHANY, P., AND REAL, L. A. 1999. Transmission bottlenecks
489 as determinants of virulence in rapidly evolving pathogens. *Proceedings of the National*
490 *Academy of Sciences* 96:5095–5100.

491 BERNGRUBER, T. W., FROISSART, R., CHOISY, M., AND GANDON, S. 2013. Evolution
492 of virulence in emerging epidemics. *PLoS Pathogens* 9.

493 BERNGRUBER, T. W., LION, S., AND GANDON, S. 2015. Spatial structure, transmission
494 modes and the evolution of viral exploitation strategies. *PLoS Pathogens* 11:e1004810.

495 BOOTS, M., HUDSON, P. J., AND SASAKI, A. 2004. Large shifts in pathogen virulence
496 relate to host population structure. *Science* 303:842–844.

497 BULL, J. J. 1994. Virulence. *Evolution* 48:1423–1437.

498 BULL, J. J. AND LAURING, A. S. 2014. Theory and empiricism in virulence evolution.
499 *PLoS Pathogens* 10:e1004387.

500 CRESSLER, C. E., MCLEOD, D. V., ROZINS, C., VAN DEN HOOGEN, J., AND DAY,
501 T. 2016. The adaptive evolution of virulence: a review of theoretical predictions and
502 empirical tests. *Parasitology* 143:915–930.

503 CROFT, D. P., EDENBROW, M., DARSEN, S. K., RAMNARINE, I. W., VAN OOSTER-
504 HOUT, C., AND CABLE, J. 2011. Effect of gyrodactylid ectoparasites on host behaviour
505 and social network structure in guppies *Poecilia reticulata*. *Behavioral Ecology and Socio-
506 biology* 65:2219–2227.

507 CURTIS, V. A. 2014. Infection-avoidance behaviour in humans and other animals. *Trends
508 in Immunology* 35:457–464.

509 DAY, T. 2001. Parasite transmission modes and the evolution of virulence. *Evolution*
510 55:2389–2400.

511 DAY, T. 2002a. The evolution of virulence in vector-borne and directly transmitted parasites.
512 *Theoretical Population Biology* 62:199–213.

513 DAY, T. 2002b. On the evolution of virulence and the relationship between various measures
514 of mortality. *Proceedings of the Royal Society of London. Series B: Biological Sciences*
515 269:1317–1323.

516 DE ROODE, J. C., YATES, A. J., AND ALTIZER, S. 2008. Virulence-transmission trade-
517 offs and population divergence in virulence in a naturally occurring butterfly parasite.
518 *Proceedings of the National Academy of Sciences* 105:7489–7494.

519 DWYER, G., LEVIN, S. A., AND BUTTEL, L. 1990. A simulation model of the population
520 dynamics and evolution of myxomatosis. *Ecological Monographs* 60:423–447.

521 EBERT, D. 1998. Experimental evolution of parasites. *Science* 282:1432–1436.

522 EBERT, D. 1999. The evolution and expression of parasite virulence. *Evolution in Health
523 and Disease* pp. 161–172.

524 EBERT, D. AND BULL, J. J. 2003. Challenging the trade-off model for the evolution of
525 virulence: is virulence management feasible? *Trends in Microbiology* 11:15–20.

526 EWALD, P. W. 1983. Host-parasite relations, vectors, and the evolution of disease severity.
527 *Annual Review of Ecology and Systematics* 14:465–485.

528 EWALD, P. W. 1994. Evolution of Infectious Disease. Oxford University Press.

529 FAUSTINO, C. R., JENNELLE, C. S., CONNOLLY, V., DAVIS, A. K., SWARTHOUT, E. C.,
530 DHONDT, A. A., AND COOCH, E. G. 2004. *Mycoplasma gallisepticum* infection dynamics
531 in a house finch population: seasonal variation in survival, encounter and transmission rate.
532 *Journal of Animal Ecology* 73:651–669.

533 FENNER, F. J. 1983. The Florey Lecture, 1983 – biological control, as exemplified by
534 smallpox eradication and myxomatosis. *Proceedings of the Royal Society of London. Series*
535 *B. Biological Sciences* 218:259–285.

536 FLEMING-DAVIES, A. E., WILLIAMS, P. D., DHONDT, A. A., DOBSON, A. P.,
537 HOCHACHKA, W. M., LEON, A. E., LEY, D. H., OSNAS, E. E., AND HAWLEY,
538 D. M. 2018. Incomplete host immunity favors the evolution of virulence in an emergent
539 pathogen. *Science* 359:1030–1033.

540 FRANK, S. A. 1996. Models of parasite virulence. *The Quarterly Review of Biology* 71:37–78.

541 FRASER, C., LYTHGOE, K., LEVENTHAL, G. E., SHIRREFF, G., HOLLINGSWORTH,
542 T. D., ALIZON, S., AND BONHOEFFER, S. 2014. Virulence and pathogenesis of hiv-
543 1 infection: an evolutionary perspective. *Science* 343.

544 FROISSART, R., DOUMAYROU, J., VUILLAUME, F., ALIZON, S., AND MICHALAKIS, Y.
545 2010. The virulence–transmission trade-off in vector-borne plant viruses: a review of (non-
546) existing studies. *Philosophical Transactions of the Royal Society B: Biological Sciences*
547 365:1907–1918.

548 FUNK, S., SALATHÉ, M., AND JANSEN, V. A. 2010. Modelling the influence of human
549 behaviour on the spread of infectious diseases: a review. *Journal of the Royal Society*
550 *Interface* 7:1247–1256.

551 KEELING, M. J., HOLLINGSWORTH, T. D., AND READ, J. M. 2020. Efficacy of contact
552 tracing for the containment of the 2019 novel coronavirus (COVID-19). *J Epidemiol*
553 *Community Health* 74:861–866.

554 KERMACK, W. O. AND MCKENDRICK, A. G. 1991. Contributions to the mathematical
555 theory of epidemics–i. 1927. *Bulletin of Mathematical Biology* 53:33–55.

556 KERR, C. C., MISTRY, D., STUART, R. M., ROSENFELD, K., HART, G. R., NÚÑEZ,
557 R. C., COHEN, J. A., SELVARAJ, P., ABEYSURIYA, R. G., JASTRZKEBSKI, M., ET AL.
558 2021. Controlling COVID-19 via test-trace-quarantine. *Nature Communications* 12:1–12.

559 LEGGETT, H. C., CORNWALLIS, C. K., BUCKLING, A., AND WEST, S. A. 2017. Growth
560 rate, transmission mode and virulence in human pathogens. *Philosophical Transactions of
561 the Royal Society B: Biological Sciences* 372:20160094.

562 LEVIN, B. R. AND BULL, J. J. 1994. Short-sighted evolution and the virulence of pathogenic
563 microorganisms. *Trends in Microbiology* 2:76–81.

564 LION, S. AND METZ, J. A. 2018. Beyond R₀ maximisation: on pathogen evolution and
565 environmental dimensions. *Trends in Ecology & Evolution* 33:458–473.

566 LIPSITCH, M. AND MOXON, E. R. 1997. Virulence and transmissibility of pathogens: what
567 is the relationship? *Trends in Microbiology* 5:31–37.

568 LOPES, P. C., BLOCK, P., AND KÖNIG, B. 2016. Infection-induced behavioural changes
569 reduce connectivity and the potential for disease spread in wild mice contact networks.
570 *Scientific Reports* 6:1–10.

571 MACKINNON, M. J. AND READ, A. F. 1999. Genetic relationships between parasite viru-
572 lence and transmission in the rodent malaria *Plasmodium chabaudi*. *Evolution* 53:689–703.

573 MAY, R. M. AND ANDERSON, R. M. 1983. Epidemiology and genetics in the coevolution
574 of parasites and hosts. *Proceedings of the Royal Society of London. Series B: Biological
575 sciences* 219:281–313.

576 MAY, R. M. AND NOWAK, M. A. 1995. Coinfection and the evolution of parasite virulence.
577 *Proceedings of the Royal Society of London. Series B: Biological Sciences* 261:209–215.

578 MCKAY, B., EBELL, M., DALE, A. P., SHEN, Y., AND HANDEL, A. 2020. Virulence-
579 mediated infectiousness and activity trade-offs and their impact on transmission potential
580 of influenza patients. *Proceedings of the Royal Society B* 287:20200496.

581 MESSENGER, S. L., MOLINEUX, I. J., AND BULL, J. J. 1999. Virulence evolution in a
582 virus obeys a trade off. *Proceedings of the Royal Society of London. Series B: Biological
583 Sciences* 266:397–404.

584 MIDEO, N., ALIZON, S., AND DAY, T. 2008. Linking within-and between-host dynamics
585 in the evolutionary epidemiology of infectious diseases. *Trends in Ecology & Evolution*
586 23:511–517.

587 NOWAK, M. A. AND MAY, R. M. 1994. Superinfection and the evolution of parasite
588 virulence. *Proceedings of the Royal Society of London. Series B: Biological Sciences* 255:81–
589 89.

590 O'DRISCOLL, M., DOS SANTOS, G. R., WANG, L., CUMMINGS, D. A., AZMAN, A. S.,
591 PAIREAU, J., FONTANET, A., CAUCHEMEZ, S., AND SALJE, H. 2021. Age-specific
592 mortality and immunity patterns of SARS-CoV-2. *Nature* 590:140–145.

593 PARRY, J. 2003. WHO warns that death rate from SARS could reach 10%. *BMJ: British*
594 *Medical Journal* 326:999.

595 READ, A. F. 1994. The evolution of virulence. *Trends in Microbiology* 2:73–76.

596 READ, A. F., BAIGENT, S. J., POWERS, C., KGOSANA, L. B., BLACKWELL, L., SMITH,
597 L. P., KENNEDY, D. A., WALKDEN-BROWN, S. W., AND NAIR, V. K. 2015. Imper-
598 fect vaccination can enhance the transmission of highly virulent pathogens. *PLoS Biol.*
599 13:e1002198.

600 REGOES, R. R., NOWAK, M. A., AND BONHOEFFER, S. 2000. Evolution of virulence in
601 a heterogeneous host population. *Evolution* 54:64–71.

602 SHAW, C. L. AND KENNEDY, D. A. 2021. What the reproductive number R_0 can and
603 cannot tell us about COVID-19 dynamics. *Theoretical Population Biology* 137:2–9.

604 STOCKMAIER, S., BOLNICK, D. I., PAGE, R. A., AND CARTER, G. G. 2020. Sickness
605 effects on social interactions depend on the type of behaviour and relationship. *Journal*
606 *of Animal Ecology* 89:1387–1394.

607 STOCKMAIER, S., STROEYMEYT, N., SHATTUCK, E. C., HAWLEY, D. M., MEYERS,
608 L. A., AND BOLNICK, D. I. 2021. Infectious diseases and social distancing in nature.
609 *Science* 371.

610 STROEYMEYT, N., GRASSE, A. V., CRESPI, A., MERSCH, D. P., CREMER, S., AND
611 KELLER, L. 2018. Social network plasticity decreases disease transmission in a eusocial
612 insect. *Science* 362:941–945.

613 SÜSS, T., REMSCHMIDT, C., SCHINK, S., LUCHTENBERG, M., HAAS, W., KRAUSE, G.,
614 AND BUCHHOLZ, U. 2011. Facemasks and intensified hand hygiene in a German household
615 trial during the 2009/2010 influenza A (H1N1) pandemic: adherence and tolerability in
616 children and adults. *Epidemiology & Infection* 139:1895–1901.

617 THOMAS, S. R. AND ELKINTON, J. S. 2004. Pathogenicity and virulence. *Journal of*
618 *Invertebrate Pathology* 85:146–151.

619 VAN KERCKHOVE, K., HENS, N., EDMUNDS, W. J., AND EAMES, K. T. D. 2013. The
620 impact of illness on social networks: implications for transmission and control of influenza.
621 *American Journal of Epidemiology* 178:1655–1662.




Figure 1: Classical formulation of the virulence-transmission trade-off. The solid curve shows a possible trade-off between transmission rate and pathogen induced host mortality rate. The evolutionarily optimal values of transmission rate β and mortality rate α according to original theory are depicted by the point where the dotted line touches the curve (Alizon et al. 2009).




Figure 2: Under the assumption that host mortality constrains virulence, moderate changes in transmission rates can justify large increases in the infection fatality rate. Open circles indicate approximate infection fatality rates for various pathogens and parasites (values are for illustration purposes and may not be exact). Filled circles indicate the maximum infection fatality rate that would be evolutionarily favored under current theory if it were accompanied by a 10% increase in the transmission rate ($\frac{\Delta\beta}{\beta_o}$). Note that this change in transmission is enough to justify an otherwise harmless pathogen evolving to become as virulent as the 2003 SARS virus.




Figure 3: Contour lines show the maximum absolute change in the infection fatality rate that would be evolutionarily favored for a given percent change in transmission rate (i.e. $\frac{\Delta\beta}{\beta_0}$). Note that when the original infection fatality rate is small (i.e. small values on x-axis) any absolute change in the infection fatality rate can be fully balanced by an equivalent percentage change in the transmission rate. The horizontal nature of the contour lines at small to moderate x-axis values indicates that costs of mortality are small unless the original infection fatality rate is large. Thus it is only when infection fatality rates before evolution are large, that increases in infection fatality pose a strong constraint on pathogen evolution.




Figure 4: A graphical representation of Inequality 14 for a pathogen with initially low virulence. The cost from an x% reduction in average transmission is equivalent to the cost from an x% increase in the infection fatality rate. The dashed line is the 1:1 line. Above the dashed line, virulence is constrained by mortality costs, and below it, detection costs. The dotted red arrow depicts the example provided in the main text of a pathogen with initially low virulence that evolves higher virulence in the form of either killing 1% of infected hosts (i.e. roughly equivalent to SARS-CoV-2 infection) or causing infected hosts to stay home for one day (roughly equivalent to infection with a virus that causes the flu or the common cold). Notably, the cost of the former is much smaller than the cost of the latter despite the fact that most would consider the former more virulent than the latter.